Publications by authors named "B E GINSBURG"

Article Synopsis
  • Alzheimer's disease is associated with impaired proteostasis, and enhancing it might help delay cognitive decline.
  • KPT-330 (Selinexor), an XPO1 inhibitor, shows promise in improving proteostasis and enhancing autophagy in neurons, leading to better memory in Alzheimer's models.
  • While KPT-330 increased overall amyloid deposition in the brain, it also resulted in lower levels of amyloid in specific areas like the thalamus, indicating that its effects on proteostasis and amyloid formation are region-specific.
View Article and Find Full Text PDF

Previously, we developed a procedure which showed that longer histories of reinforced alternative behavior decrease the risk of relapse caused by a range of stimuli which had previously occasioned drinking. The decrease in relapse risk was likely due to a decrease in attention to the stimuli over the course of repeated engagement in the alternative behavior. However, this previous procedure was time consuming and did not mirror the procedure we used to observe changes in relapse risk.

View Article and Find Full Text PDF

The hypothalamus undergoes significant changes with aging and plays crucial roles in age-related metabolic alterations. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are anti-diabetic agents that promote glucose excretion, and metabolic homeostasis. Recent studies have shown that a SGLT2i, Canagliflozin (Cana), can extend the median survival of genetically heterogeneous UM-HET3 male mice and improve central metabolic control via increases in hypothalamic insulin responsiveness in aged males, as well as reduced age-associated hypothalamic inflammation.

View Article and Find Full Text PDF

Genetically heterogeneous UM-HET3 mice born in 2020 were used to test possible lifespan effects of alpha-ketoglutarate (AKG), 2,4-dinitrophenol (DNP), hydralazine (HYD), nebivolol (NEBI), 16α-hydroxyestriol (OH_Est), and sodium thiosulfate (THIO), and to evaluate the effects of canagliflozin (Cana) when started at 16 months of age. OH_Est produced a 15% increase (p = 0.0001) in median lifespan in males but led to a significant (7%) decline in female lifespan.

View Article and Find Full Text PDF